سنغافورة - الإنجليزية - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - diphtheria toxoid; filamentous haemagglutinin; hepatitis b surface antigen (purified); hib purified capsular polysaccharide bound to tetanus toxoid; pertactin (69 kda omp); pertussis toxoid; poliovirus type 1 (inactivated); poliovirus type 2 (inactivated); poliovirus type 3 (inactivated) - injection - min 30 iu/0.5 ml - diphtheria toxoid min 30 iu/0.5 ml; filamentous haemagglutinin 25 mcg/0.5 ml; hepatitis b surface antigen (purified) 10 mcg/0.5 ml; hib purified capsular polysaccharide bound to tetanus toxoid 10 mcg/0.5 ml; pertactin (69 kda omp) 8 mcg/0.5 ml; pertussis toxoid 25 mcg/0.5 ml; poliovirus type 1 (inactivated) 40 du/0.5 ml; poliovirus type 2 (inactivated) 8 du/0.5 ml; poliovirus type 3 (inactivated) 32 du/0.5 ml

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

vetter pharma fertigung gmbh & co. kg - japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (unii: dz854i04ze) (japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) - unii:dz854i04ze) - japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) 6 ug in 0.5 ml

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis b surface antigen recombinant, quantity: 20 microgram/ml; hepatitis a virus antigen, quantity: 720 elisa unit/ml - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; aluminium phosphate; polysorbate 20; water for injections; neomycin sulfate; monobasic sodium phosphate; trometamol; sodium chloride; dibasic sodium phosphate heptahydrate; formaldehyde solution; acetic acid; leucine; phenylalanine; methionine; lysine hydrochloride; isoleucine; valine; histidine; threonine; tryptophan; alanine; arginine; proline; tyrosine; serine; sodium acetate; dibasic potassium phosphate; magnesium chloride hexahydrate; glycine - twinrix (720/20) is indicated for active immunisation against hepatitis a and hepatitis b virus infection in adults and children from 1 year of age. twinrix junior (360/10) is indicated for use in children aged 1 to 15 years. twinrix (720/20) is indicated for active immunisation against hepatitis a and hepatitis b virus infection in adults and children from 1 year of age. twinrix junior (360/10) is indicated for use in children aged 1 to 15 years.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis b surface antigen recombinant, quantity: 20 microgram/ml; hepatitis a virus antigen, quantity: 720 elisa unit/ml - injection, suspension - excipient ingredients: trometamol; aluminium hydroxide hydrate; sodium chloride; polysorbate 20; neomycin sulfate; water for injections; formaldehyde solution; aluminium phosphate; dibasic sodium phosphate heptahydrate; monobasic sodium phosphate; acetic acid; leucine; phenylalanine; methionine; lysine hydrochloride; isoleucine; valine; histidine; threonine; tryptophan; alanine; arginine; proline; tyrosine; serine; sodium acetate; dibasic potassium phosphate; magnesium chloride hexahydrate; glycine - twinrix (720/20) is indicated for active immunisation against hepatitis a and hepatitis b virus infection in adults and children from 1 year of age. twinrix junior (360/10) is indicated for use in children aged 1 to 15 years. twinrix (720/20) is indicated for active immunisation against hepatitis a and hepatitis b virus infection in adults and children from 1 year of age. twinrix junior (360/10) is indicated for use in children aged 1 to 15 years.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

viatris limited - influenza virus a/darwin/9/2021 (h3n2)-like strain 15ug (a/darwin/9/2021, san 010); influenza virus a/sydney/5/2021 (h1n1) pdm09-like strain 15ug (a/sydney/5/2021, san 013); influenza virus b/austria/1359417/2021-like strain 15ug (b/austria/1359417/2021, bvr-26); influenza virus b/phuket/3073/2013 - like strain 15ug (b/phuket/3073/2013, wild type) - suspension for injection - 0.5 ml - active: influenza virus a/darwin/9/2021 (h3n2)-like strain 15ug (a/darwin/9/2021, san 010) influenza virus a/sydney/5/2021 (h1n1) pdm09-like strain 15ug (a/sydney/5/2021, san 013) influenza virus b/austria/1359417/2021-like strain 15ug (b/austria/1359417/2021, bvr-26) influenza virus b/phuket/3073/2013 - like strain 15ug (b/phuket/3073/2013, wild type) excipient: calcium chloride dihydrate dibasic sodium phosphate as dihydrate 0.67 mg magnesium chloride hexahydrate monobasic potassium phosphate potassium chloride sodium chloride water for injection - for the prevention of influenza caused by influenza virus, types a and b. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines. influvac tetra is indicated in adults and children from 6 months of age and older.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - tetanus toxoid, quantity: 40 iu; pertussis fimbriae 2 + 3, quantity: 5 microgram; diphtheria toxoid, quantity: 30 iu; poliovirus, quantity: 29 dagu; poliovirus, quantity: 26 dagu; poliovirus, quantity: 7 dagu; pertussis toxoid, quantity: 20 microgram; pertactin, quantity: 3 microgram; pertussis filamentous haemagglutinin, quantity: 20 microgram - injection, suspension - excipient ingredients: polymyxin b sulfate; bovine serum albumin; formaldehyde; phenoxyethanol; glutaral; neomycin; water for injections; polysorbate 80; aluminium phosphate - quadracel is indicated for primary immunisation of children from the age of 2 months to 12 months against diphtheria, tetanus, pertussis, and poliomyelitis.,quadracel is also indicated for the fourth dose for children from 15 months to six years of age who have been immunised previously with three doses of diphtheria, tetanus, pertussis and polio vaccines.

مالطا - الإنجليزية - Medicines Authority

jv healthcare limited navi buidlings, pantar road, lija, lja 2021, malta - tick, borne encephalitis, virus - suspension for injection in pre-filled syringe - tick-borne encephalitis virus 1,2 2.4mcg / 0.5ml - vaccines

مالطا - الإنجليزية - Medicines Authority

jv healthcare limited navi buidlings, pantar road, lija, lja 2021, malta - tick, borne encephalitis, virus - suspension for injection in pre-filled syringe - tick-borne encephalitis virus 1,2 1.2mcg / 0.5ml - vaccines

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - tick-borne encephalitis purified antigen (formaldehyde inactivated) (unii: 42xd79uqq6) (tick-borne encephalitis purified antigen (formaldehyde inactivated) - unii:42xd79uqq6) - ticovac™ is indicated for active immunization to prevent tick-borne encephalitis (tbe). ticovac is approved for use in individuals 1 year of age and older. severe allergic reaction (e.g. anaphylaxis) to any component of ticovac [see description (11)]. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. there are no adequate and well-controlled studies of ticovac in pregnant women. available human data are insufficient to establish the presence or absence of vaccine-associated risk during pregnancy. developmental and reproductive toxicity studies in animals have not been conducted with ticovac. risk summary human data are not available to assess the impact of ticovac on milk production, its presence in breast milk, or its effects on the breastfed. the developmental and health benefits of breastfee

سنغافورة - الإنجليزية - HSA (Health Sciences Authority)

aenon pharmaceuticals sea pte. ltd. - inactivated rabies virus (strain flury lep) - injection, powder, lyophilized, for solution - potency≥2.5iu - inactivated rabies virus (strain flury lep) potency≥2.5iu